Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis : first results of the Berlin Multi-Centre FST Validation Study
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis : first results of the Berlin Multi-Centre FST Validation Study
Journal
Multiple sclerosis journal
Volume
13
Number
3
Pages / Article-Number
402-11
Keywords
cognitive impairment, Faces Symbol Test, multiple sclerosis, neuropsychology, PASAT, screening test
Abstract
Reliable, language-independent, short screening instruments to test for cognitive function in patients with multiple sclerosis (MS) remain rare, despite the high number of patients affected by cognitive decline. We developed a new, short screening instrument, the Faces Symbol Test (FST), and compared its diagnostic test characteristics with a composite of the Digit Symbol Substitution Test (DSST) and the Paced Auditory Serial Addition Test (PASAT), in 108 MS patients and 33 healthy controls. An Informant-Report Questionnaire, a Self-Report Questionnaire, and a neurologist's estimation of the Every Day Life Cognitive Status were also applied to the MS patients. The statistical analyses comprised of a receiver operating characteristic analysis for test accuracy and for confounding variables. The PASAT and DSST composite score estimated that 36.5% of the MS patients had cognitive impairment. The FST estimated that 40.7% of the MS patients were cognitively impaired (sensitivity 84%; specificity 85%). The FST, DSST and PASAT results were significantly correlated with the patients' physical impairment, as measured by the Expanded Disability Status Scale (EDSS). The results suggest that the FST might be a culture-free, sensitive, and practical short screening instrument for the detection of cognitive decline in patients with MS, including those in the early stages.
